All sponsors

Immunovant Sciences GmbH

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO0%

Delay Index: of 7 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Immunovant Sciences GmbH on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
IMVT-1402
NCT06980805
P2Active, not recruitingSubacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus562026-10 (-6 mo)
IMVT-1402
NCT07018323
P2RecruitingGraves' Disease2102027-05
IMVT-1402
NCT06754462
P2Active, not recruitingRheumatoid Arthritis1202027-09
IMVT-1402
NCT07039916
P3RecruitingGeneralized Myasthenia Gravis2312027-12
IMVT-1402
NCT06727604
P2RecruitingGraves' Disease2402028-06
IMVT-1402
NCT06979531
P2Active, not recruitingPrimary Sjögren's Syndrome1802028-07
Imeroprubart
NCT07032662
P2RecruitingChronic Inflammatory Demyelinating Polyneuropathy1622028-08
IMVT-1402
NCT07286006
P2Enrolling by invitationGraves' Disease3722030-03